


# 9.2. Update on Patient Experience Data – Reflection Paper

Presented by Kaisa Immonen

PCWP/HCPWP joint meeting, 1-2 April 2025



# What is patient experience data (PED)

- **Data reported directly by patients or their carers** without interpretation by clinicians or third parties
- **Reflects patients' experience of their health conditions and** preferences on medicines
- **Proposal for an EU definition** as part of the [EMA 2022 workshop](#)
  - Definition to be agreed with stakeholders
- **Types of PED:**
  - Patient-reported outcomes (PRO), patient preference studies (PPS), data from patient engagement
  - Quantitative and qualitative data, clinical trials or real world data (RWD) contexts

# Patient experience data in the EU




- Reinforcing patient relevance in evidence generation is a key priority in the [Regulatory Science Strategy](#) and the European medicines agencies network strategy (See [EMANS to 2025](#) and [EMANS to 2028](#))
- Collection of PED using reliable and validated methodologies can contribute to benefit/risk evaluation to complement and support primary or secondary endpoints
- PED also relevant for implementation of the EU HTA regulation in value assessments that inform subsequent decisions by payers
- Post-approval PED can be collected as part of RWD (e.g. registries, patient reports) to generate evidence

# Opportunities to improve

- Despite progress in recent years, PED are still not systematically included in all aspects of medicines development and regulation
- Stakeholder calls for progress and guidance from EMA to ensure the EU does not stay behind
- To optimise the use of PED, more work needed especially on:
  - Data collection methods
  - Data quality and completeness
  - Methodologies applied to PED




# Progress in PED



# Reflection paper on EU approach to PED

- **Framework for discussion** or clarification particularly in areas where scientific knowledge is fast evolving or regulatory experience is limited
- **Key action** derived from the 2022 PED workshop – requested by stakeholders
- **General EU framework or principles** – not a methodological guidance – complementary to ICH guidance work
- **Internal consultation** (incl. circulation to **PCWP/HCPWP**) in **March 2025**
- **Public consultation foreseen** in Q3 2025



EUROPEAN MEDICINES AGENCY  
SCIENCE · MEDICINES · HEALTH

1 Reflection paper on patient experience data in the EU

2

Draft reviewed by CHMP, PRAC, PCWP, HCPWP, SAWP, MWP, ONCWP, RWP, CVSWP, CNSWP, IDWP, VWP, NDSG, COMP, CAT, PDCC, ETF and CTCG	by 31 March
Review by Guideline consistency group (GCG)	5-May to 15-June
Adoption by PRAC and CHMP for release for consultation	Planned July 2025
Start of public consultation	Planned 25-31 July 2025
End of consultation (deadline for comments)	31-October-2025
Agreed by <Working Party>	
Adoption by <Committee> CHMP, PRAC	Planned Feb-March 2026

3 Comments should be provided using <tb>. The completed comments form should be sent to [PED\\_RP@ema.europa.eu](mailto:PED_RP@ema.europa.eu)

4

<b>Keywords</b>	<i>Patient Experience Data, Patient Engagement, Patient Reported Outcomes, Patient Preference Studies, Patient-generated digital data, clinical trials, real world data</i>
-----------------	---

5

6

Official address: Domenico Scarlatti laan 6 • 1083 HS Amsterdam • The Netherlands  
Address for visits and deliveries: Refer to [www.ema.europa.eu/how-to-find-us](http://www.ema.europa.eu/how-to-find-us)  
Send us a question: Go to [www.ema.europa.eu/contact](http://www.ema.europa.eu/contact) • Telephone: +31 (0)85 753 4000 • Fax: +31 (0)85 753 4000  
© European Medicines Agency, 2025. Reproduction is authorised provided the source is acknowledged.

# Structure of the reflection paper

1. Introduction, Problem Statement and Scope
2. The EU regulatory approach to PED
  - Definition of PED
  - Scientific advice and qualification, Innovation Task Force, academia support
3. Use and value of PED along the medicine's lifecycle
4. Sources of PED (clinical trials, real-world settings)
5. Methods to generate and collect PED (PROs, PPS, patient engagement)
6. Considerations for systematic implementation (e.g. methodological, operational, acceptance/trust, global development)

Table of contents

<b>1. Introduction, Problem Statement and Scope</b> .....	<b>3</b>
1.1. Introduction .....	3
1.2. Problem statement .....	3
1.3. Scope .....	3
<b>2. The EU regulatory approach to patient experience data</b> .....	<b>4</b>
2.1. Patient experience data .....	4
2.2. EU regulators' view on PED.....	4
2.2.1. EMA's Innovation Task Force and academia support/briefing meetings.....	5
2.2.2. EMA scientific advice and qualification of novel methodologies .....	5
<b>3. Use and value of PED along the medicine's lifecycle</b> .....	<b>6</b>
<b>4. Sources of Patient Experience Data</b> .....	<b>7</b>
4.1. PED collected in clinical trials .....	7
4.2. Real World Data as a source of PED .....	8
4.3. Safety surveillance systems.....	8
4.4. Other potential sources of PED.....	8
<b>5. Methods to generate and collect PED</b> .....	<b>9</b>
5.1. Patient-reported outcomes .....	9
5.2. Patient Preference Studies .....	10
5.2.1. Qualitative PPS .....	10
5.2.2. Quantitative PPS .....	11
5.3. Patient Engagement activities .....	11
<b>6. Considerations for systematic PED implementation</b> .....	<b>14</b>
6.1. Methodological considerations.....	14
6.2. Operational considerations .....	15
6.3. Lack of trust.....	17
6.4. Transparency on the use of PED in regulatory assessment.....	17
6.5. Global alignment on patient experience data .....	17
<b>7. Conclusions</b> .....	<b>17</b>
<b>8. References</b> .....	<b>18</b>
<b>9. Glossary</b> .....	<b>22</b>

Reflection paper on patient experience data in the EU  
EMA/468226/2024

Page 2/23

# Conclusions

- **EU regulators welcome PED** as important contribution to the totality of evidence and are working collaboratively to enable its broader use in regulatory decision-making
- **PED must be of high quality** to meet regulatory requirements
  - Scientific advice + qualification of novel methodologies
  - Contributing to methodological work and guidance/harmonisation via ICH
- **Increased transparency** on PED in the CHMP Assessment Report
- **EMA reflection paper** to be published in **Q3 2025** for 3-month consultation
  - Comments already received from some PCWP/HCPWP members
  - Further input will be welcomed



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

# Thank you

Follow us

